Country: Canada
Language: English
Source: Health Canada
PORACTANT ALFA
CHIESI FARMACEUTICI S.P.A.
R07AA02
NATURAL PHOSPHOLIPIDS
80MG
SUSPENSION
PORACTANT ALFA 80MG
INTRATRACHEAL
15G/50G
Prescription
PULMONARY SURFACTANTS
Active ingredient group (AIG) number: 0139601001; AHFS:
APPROVED
2001-09-11
_Curosurf_ _®_ _ Product Monograph _ _Page 1 of 32_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr CUROSURF ® poractant alfa Suspension, 80 mg surfactant/mL, Intratracheal Lung Surfactant (Porcine) MANUFACTURER: Chiesi Farmaceutici, S.p.A. 26/A Via Palermo Parma 43122 Italy IMPORTED AND DISTRIBUTED BY: Methapharm Inc. 81 Sinclair Boulevard Brantford, ON, N3S 7X6 Date of Initial Approval: January 17, 2000 Date of Revision: July 22, 2021 Submission Control No: 241424 _Curosurf_ _®_ _ Product Monograph _ _Page 2 of 32_ RECENT MAJOR LABEL CHANGES Indications, Pediatrics (1.0) 06/2021 Serious Warnings and Precautions (3.0) 06/2021 Dosage and Administration, Dosing Considerations (4.1) 06/2021 Dosage and Administration, Administration (4.3) 06/2021 Warnings and Precautions, General (8.0) 06/2021 Warnings and Precautions, Immune (8.0) 06/2021 Warnings and Precautions, Ophthalmologic (8.0) 06/2021 _Curosurf_ _®_ _ Product Monograph _ _Page 3 of 32_ TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ................................................................................ 2 TABLE OF CONTENTS....................................................................................................... 3 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 5 1 INDICATIONS ........................................................................................................... 5 1.1 Pediatrics .......................................................................................................... 5 1.2 Geriatrics .......................................................................................................... 5 2 CONTRAINDICATIONS ........................................................................................... 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .............................................. 6 4 DOSAGE AND ADMINISTRATION ......................................................................... 6 4.1 Dosing Considerations...................... Read the complete document